A phase 1 randomized placebo-controlled safety and pharmacokinetic trial of a tenofovir disoproxil fumarate vaginal ring

  • Keller M
  • Mesquita P
  • Marzinke M
 et al. 
  • 3


    Mendeley users who have this article in their library.
  • N/A


    Citations of this article.


Background: Tenofovir disoproxil fumarate (TDF), a prodrug of tenofovir (TFV), may be ideal for topical HIV preexposure prophylaxis because it has higher tissue and cell permeability than TFV; is not adversely impacted by seminal proteins; and its active metabolite, TFV-diphosphate (TFV-DP), has a long intracellular half-life. We engineered a TDF eluting polyurethane reservoir intravaginal ring (IVR) to provide near constant mucosal antiretroviral concentrations. Methods: A first-in-human randomized placebo-controlled trial was conducted to assess the safety and pharmacokinetics of the TDF IVR in healthy, sexually abstinent women (15 TDF and 15 placebo). Drug concentrations were measured in cervicovaginal fluid (CVF) obtained by swab, cervical tissue, plasma, and dried blood spots (DBS) over 14 days of continuous ring use. Results: There were 43 total, 23 reproductive tract, and eight product-related grade 1 adverse events. Steady-state CVF TFV concentrations were achieved proximal (vagina, ectocervix) and distal (introitus) to the TDF IVR 1 day after ring insertion. Median tissue TFV-DP concentrations 14 days after TDF IVR placement were 120fmol/mg (interquartile range 90, 550). CVF collected from the cervix 1 week and 2 weeks after TDF IVR insertion provided significant protection against ex-vivo HIV challenge. Eleven of 14 (78%) participants had detectable TFV-DP DBS concentrations 14 days after TDF IVR placement, suggesting that DBS may provide a surrogate marker of adherence in future clinical trials. Conclusion: A TDF IVR is safe, well tolerated, and results in mucosal TFV concentrations that exceed those associated with HIV protection. The findings support further clinical evaluation of this TDF IVR.

Author-supplied keywords

  • Human immunodeficiency virus infection/dt [Drug Th
  • Human immunodeficiency virus infection/pc [Prevent
  • adult
  • antiviral activity
  • article
  • controlled study
  • disease marker
  • dried blood spot testing
  • drug safety
  • ex vivo study
  • female
  • human
  • metrorrhagia/co [Complication]
  • metrorrhagia/si [Side Effect]
  • nonhuman
  • pharmacodynamics
  • phase 1 clinical trial
  • placebo
  • priority journal
  • protocol compliance
  • randomized controlled trial
  • sexual abstinence
  • tenofovir disoproxil/ae [Adverse Drug Reaction]
  • tenofovir disoproxil/ct [Clinical Trial]
  • tenofovir disoproxil/dt [Drug Therapy]
  • tenofovir disoproxil/pd [Pharmacology]
  • tenofovir disoproxil/pk [Pharmacokinetics]
  • tenofovir disoproxil/pr [Pharmaceutics]
  • tenofovir disoproxil/va [Intravaginal Drug Adminis
  • uterine cervix mucus
  • vagina discharge/co [Complication]
  • vagina discharge/si [Side Effect]
  • vagina ring
  • vagina smear
  • vaginitis/co [Complication]
  • vaginitis/si [Side Effect]

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • Mj Keller

  • Pm Mesquita

  • Ma Marzinke

  • R Teller

  • L Espinoza

  • Jm Atrio

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free